Compass Therapeutics Inc. (CMPX)

Sep 26, 2026

Compass Therapeutics' Chief Accounting Officer, Neil Lerner, recently purchased 2,500 shares, increasing his total ownership to 400,000 shares. This transaction is part of a larger trend of insider buying at CMPX, with 3 buys and 0 sells over the past year, indicating a positive outlook from insiders. Additionally, GuruFocus data shows 4 gurus holding CMPX shares, with most adding to their positions, further suggesting confidence in the clinical-stage biopharmaceutical company despite the inherent risks of drug development.

Sep 25, 2026

Compass Therapeutics, Inc. (CMPX) is drawing market attention after the FDA recommended an additional survival study for its tovecimig biologics application in biliary tract cancer. The article highlights that the market will focus on the company's execution, customer response, and how sector conditions and competitive pressures affect its operations following this development. Investors are advised to look for consistent delivery and operational evidence in future disclosures rather than just the initial announcement.

Sep 22, 2026

Compass Therapeutics announced that the FDA has recommended an additional trial demonstrating a survival benefit for tovecimig in biliary tract cancer patients before a BLA submission. Despite this, Compass intends to proceed with BLA preparations, citing significant improvements in ORR and PFS from their COMPANION-002 study and the urgent unmet medical need. The company remains confident in tovecimig's potential, believing the existing data supports its clinical meaningfulness.